BioCryst Pharmaceuticals BCRX Operating Lease Liability Payments - 2025 (Lessee)

Operating Lease Liability Payments - 2025 (Lessee) at other companies

BridgeBio PharmaBBIO

——

Agios PharmaceuticalsAGIO

——

PrecigenPGEN

——

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's operating lease liability payments - 2025 (lessee).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's operating lease liability payments - 2025 (lessee)?: BioCryst Pharmaceuticals (BCRX) reported operating lease liability payments - 2025 (lessee) of $1.59M in Q1 2026.
How has BioCryst Pharmaceuticals's operating lease liability payments - 2025 (lessee) changed year-over-year?: BioCryst Pharmaceuticals's operating lease liability payments - 2025 (lessee) increased by 59.6% year-over-year, from $996K to $1.59M.